Home
About
Our Mission
Leadership
Board of Directors
Scientific Advisory Board
Science
Our Approach
The B Cell Advantage
Research
Pipeline
Investors & Media
Press Releases
News Articles
Publications & Presentations
Contact
Careers
Home
About
Our Mission
Leadership
Board of Directors
Scientific Advisory Board
Science
Our Approach
The B Cell Advantage
Research
Pipeline
Investors & Media
Press Releases
News Articles
Publications & Presentations
Contact
Careers
News
All
Press Releases
News Articles
Press Releases
October 07, 2025
In a Major Breakthrough for Cell and Gene Therapy, Immusoft Has Re-dosed a Patient with ISP-001 in Its Lead Program for MPS I
Related
Press Releases
PR Newswire | October 21, 2025
Immusoft Receives FDA Fast Track Designation for ISP-001, a First-in-Class Engineered B Cell Therapy for MPS I
Read More
Publications & Presentations
Beyond Biotech | May 20, 2025
Fighting mucopolysaccharidosis type I, a rare disease, by reprogramming B-cells
Read More
